Distribution of total <i>T. colubriformis</i> recovered after 48 hours, stratified by height zone. by Katy A. Martin (9216905)

Loss of MALS-1 function suppresses the mitochondrial and axon degeneration phenotypes that are caused by loss of RBM-26 function. by Tamjid A. Chowdhury (14149846)

“…Asterisks indicate statistically significant difference relative to wild type, Student’s <i>t</i> test (*<i>p</i> < 0.05). …”

The growth of co-transformed cells in the peritoneal cavity alters viral gene expression to mirror that of PEL cell lines. by Mitchell Hayes (5334887)

Overexpression of MALS-1 reduces mitochondria in the PLM axon and causes axon degeneration and axon overlap defects. by Tamjid A. Chowdhury (14149846)

“…Asterisks in panels D and E indicate statistically significant difference relative to wild type, Z-test for proportions (***<i>p</i> < 0.0001). …”

The growth of co-transformed cells in the peritoneal cavity alters their cellular gene expression to mirror that of PEL biopsies. by Mitchell Hayes (5334887)

Co-infected cells express both KSHV and EBV genes <i>in vitro</i> necessary for their survival and growth. by Mitchell Hayes (5334887)

Loss of RBM-26 causes mitochondria dysfunction in PLM. by Tamjid A. Chowdhury (14149846)

RBM-26 is expressed in the PLM and functions within neurons to protect against axon degeneration and prevent axon overlap defects. by Tamjid A. Chowdhury (14149846)

Mutations in <i>rbm-26</i> cause axon degeneration and axon overlap defects. by Tamjid A. Chowdhury (14149846)

Summary of Biomarker Expression in Benign Samples. The STT and LTT groups exhibit significant changes in biomarker expression compared to the nontreatment group, measured on a two-... by Jinho Lee (587173)

Subjects:

Proportion of stillbirths in Stockholm among twin and singleton pregnancies. by Matilda Varli Hjärne (22766125)

Loss of RBM-26 function causes a reduction in the density of mitochondria in the PLM axon. by Tamjid A. Chowdhury (14149846)

HBV RNaseH inhibitors effects on capsid accumulation occur independent of HBV DNA synthesis. by Daniel P. Bradley (10306893)

Table 2_A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.xlsx by Ya-Jun Zhang (1625761)

“…Current research on PPI-associated tumor adverse events (TAEs) is limited and inconclusive. …”

Table 1_A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database.xlsx by Ya-Jun Zhang (1625761)

“…Current research on PPI-associated tumor adverse events (TAEs) is limited and inconclusive. …”

Co-transformed cells grow preferentially as tumors in peritoneal cavities. by Mitchell Hayes (5334887)

Expression of RBM-26 is disrupted by P80L and L13V missense mutations. by Tamjid A. Chowdhury (14149846)

Effects of 1466 on capsid and pgRNA encapsidation compared to known CAM-A and CAM-E inhibitors. by Daniel P. Bradley (10306893)

Screening HBV RNaseH inhibitors in HepDES19 cell for effects on capsids and core protein. by Daniel P. Bradley (10306893)

1466 inhibits capsid accumulation independent of HBV replication. by Daniel P. Bradley (10306893)